Compare Janus Living Inc. Class A-1 Common Stock (JAN) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Janus Living Inc. Class A-1 Common Stock vs Kymera Therapeutics Inc. Common Stock — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $28.51 (market cap $6.76B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Janus Living Inc. Class A-1 Common Stock pays a 1.98% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| JAN | KYMR | |
|---|---|---|
Market Cap | $6.76B | $8.87B |
Volume | 1,332,082 | 779,107 |
Sector | Real Estate | Health |
52-Week High | $31.76 | $127.31 |
52-Week Low | $22.88 | $55.80 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.85B | $8.26B |
Dividend Yield | 1.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
